Imperial College London
Alternate

Emeritus ProfessorMustafaDjamgoz

Faculty of Natural Sciences, Department of Life Sciences

Emeritus Professor in Cancer Biology
 
 
 
//

Contact

 

+44 (0)20 7594 5370m.djamgoz

 
 
//

Location

 

Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Jentzsch:2020:10.3390/cancers12113096,
author = {Jentzsch, V and Davis, JAA and Djamgoz, MBA},
doi = {10.3390/cancers12113096},
journal = {Cancers},
pages = {1--62},
title = {Pancreatic Cancer (PDAC): introduction of evidence-based complementary measures into integrative clinical management},
url = {http://dx.doi.org/10.3390/cancers12113096},
volume = {12},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The most common form of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC), which comprises some 85% of all cases. Currently, this is the fourth highest cause of cancer mortality worldwide and its incidence is rising steeply. Commonly applied clinical therapies offer limited chance of a lasting cure and the five-year survival rate is one of the lowest of the commonly occurring cancers. This review cultivates the hypothesis that the best management of PDAC would be possible by integrating ‘western’ clinical medicine with evidence-based complementary measures. Protecting the liver, where PDAC frequently first spreads, is also given some consideration. Overall, the complementary measures are divided into three groups: dietary factors, nutraceutical agents and lifestyle. In turn, dietary factors are considered as general conditioners, multi-factorial foodstuffs and specific compounds. The general conditioners are alkalinity, low-glycemic index and low-cholesterol. The multi-factorial foodstuffs comprise red meat, fish, fruit/vegetables, dairy, honey and coffee. The available evidence for the beneficial effects of the specific dietary and nutraceutical agents was considered at four levels (in order of prominence): clinical trials, meta-analyses, in vivo tests and in vitro studies. Thus, 9 specific agents were identified (6 dietary and 3 nutraceutical) as acceptable for integration with gemcitabine chemotherapy, the first-line treatment for pancreatic cancer. The specific dietary agents were the following: Vitamins A, C, D and E, genistein and curcumin. As nutraceutical compounds, propolis, triptolide and cannabidiol were accepted. The 9 complementary agents were sub-grouped into two with reference to the main ‘hallmarks of cancer’. Lifestyle factors covered obesity, diabetes, smoking, alcohol and exercise. An integrative treatment regimen was devised for the management of PDAC patients. This involved combining first-line gemcitabine chem
AU  - Jentzsch,V
AU  - Davis,JAA
AU  - Djamgoz,MBA
DO  - 10.3390/cancers12113096
EP  - 62
PY  - 2020///
SN  - 2072-6694
SP  - 1
TI  - Pancreatic Cancer (PDAC): introduction of evidence-based complementary measures into integrative clinical management
T2  - Cancers
UR  - http://dx.doi.org/10.3390/cancers12113096
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592911300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.mdpi.com/2072-6694/12/11/3096
UR  - http://hdl.handle.net/10044/1/91184
VL  - 12
ER  -
Download